IM VETERINARIA #32

67 im veterinaria BIBLIOGRAFÍA: Brioschi, F. A., Di Cesare, F., Gioeni, D., Rabbogliatti, V., Ferarri, F., D’Urso, E. S., Ravasio, G. (2020, August 26). Oral Transmucosal Cannabidiol Oil Formulation as Part of aMultimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Im- provement in Dogs Affected by Spontaneous Osteoarthritis. Animals, 10(1505), 1-14. doi:doi:10.3390/ani10091505 Chicoine, A., Illing, K., Vuong, S., Pinto, K. R., Alcorn, J., & Cosford, K. (2020, September 29). Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. Frontiers in Veterinary Science, 7. doi:doi: 10.3389/fvets.2020.583404 Deabold, K. S. (2019). Single-Dose Pharmacokinetics and Preliminary Safety Assess- ment withUse of CBD-RichHempNutraceutical inHealthyDogs andCats. Animals, 9, 832. doi :https://www.mdpi.com/2076-2615/9/10/832 Di Marzo, V. W. (2015). The Endocannabinoidome - The World of Endocannabi- noids and Related Mediators (First ed.). (V. D. Wang, Ed.) Elsevier Inc. doi:https://doi. org/10.1016/C2013-0-13461-7 FundaciónCanna. (2021, 01 02). ¿Qué son los cannabinoides? ¿Dónde se encuentran? Retrieved 01 02, 2021, fromFundaciónCanna: https://www.fundacion-canna.es/can- nabinoides Fuss, J., Steinle, J., Auer, M., Gass, P., Kirchner, H., Lutz, B., & Bindila, L. (2015, October). A runner’s high depends on cannabinoid receptors in mice. Proceedings of the Natio- nal Academy of Sciences of the United States of America. doi :https://doi.org/10.1073/ pnas.1514996112 Gallily, R. Y. (2015). Overcoming the Bell-Shaped Dose-Response of Cannabidiol by UsingCannabis Extract Enriched inCannabidiol. Pharmacology&Pharmacy, 6, 75-85. doi:10.4236/pp.2015.62010 Gamble, L.-J. B. (2018). Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Frontiers in Veterinary Science, 5, 165. doi:10.3389/ fvets.2018.00165 GW Pharmaceuticals. (2018). U. S. Food & Drug Administration. Retrieved 2020, from Drug Approval Package: Epidiolex (Cannabidiol): https://www.accessdata.fda.gov/ drugsatfda_docs/nda/2018/210365Orig1s000PharmR.pdf Hannon, M. B., Deabold, K. A., Talsma, B. N., Lyubimov, A., Iqbal, A., Zakharov, A., . . . Wakshlag, J. J. (2020, July 31). Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sa- tiva extract in beagles. Veterinary Pharmacology and Therapeutics, 43(5), 508-511. doi :https://doi.org/10.1111/jvp.12896 Hohmann, A. F. (2004). Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. Journal of Pharmacology and Experi- mental Therapeutics, 308, 446–453. Hughston, L. (2019). Scooby’s Doobies: Cannabis Use inVeterinaryMedicine. Ibrahim, M. D. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proceedings of theNational Academy of Sciences of theUnited States of America, 100, 10529–10533. Jung, K. P. (2015). Cannabinoids and Endocannabinoids. InV. N. PfaffD., Neuroscience in the 21st Century. New York, NY: Springer. doi :https://doi.org/10.1007/978-1-4614- 6434-1_136-1 Kogan, L., Hellyer, P., & Downing, R. (2020). The Use of Cannabidiol-Rich Hemp Oil Ex- tract toTreatCanineOsteoarthritis-RelatedPain: APilot Study. Journal of theAmerican Holistic VeterinaryMedical Association, 58, 35-45. Retrieved fromhttps://www.resear- chgate.net/publication/339698157_The_Use_of_Cannabidiol-Rich_Hemp_Oil_Ex- tract_to_Treat_Canine_Osteoarthritis-Related_Pain_A_Pilot_Study Lauckner, J. J. (2008, February 19). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proceedings of the National Academy of Sciences of the United States of America, 105(7), 2699-2704. Retrieved from https:// www.pnas.org/content/105/7/2699 Mechoulam, R. (. (2005). Cannabinoids as Therapeutics. Basel: Birkhäuser Verlag. Morales, P. H. (2017). Molecular Targets of the Phytocannabinoids: A Complex Picture. In K. AD, F. H, G. S, & K. J, Phytocannabinoids, Unraveling the Complex Chemistry and Pharmacologyof Cannabis sativa (Vol. 103, pp. 104-131). Cham, Switzerland: Springer Nature. Porter, A. S. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Journal of Pharmacology and Experimental Therapeutics, 301, 1020–1024. Reggio, P. (2010). Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown. Current Medicinal Chemistry, 17(14), 1468 - 1486. doi:10.2174/092986710790980005 Russo, E. B. (2011). Taming THC - Potential Cannabis Synergy and Phytocannabi- noid-Terpenoid Entourage Effects. British Journal of Pharmacology, 163, 1344-1364. doi :http://dx.doi.org/10.1111/j.1476-5381.2011.01238.x Russo, E. B. (2018). TheCase for the Entourage Effect andConventional Breedingof Cli- nical Cannabis: No “Strain,” No Gain. Frontiers in Plant Science, 9, 1969. doi:10.3389/ fpls.2018.01969 Sanguinetti, M., Posteraro, B., Romano, L., Battaglia, F., Lopizzo, T., de Carolis, E., & Fad- da, G. (2007). Invitroactivity of Citrus bergamia (bergamot) oil against clinical isolates of dermatophytes. Journal of Antimicrobial Chemotherapy, 305-8. Vaughn, D., Kulpa, J., & Paulionis, L. (2020, February 11). Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs. Frontiers in Veterinary Science, 7(51). doi :https://doi.org/10.3389/fvets.2020.00051 Verrico, C. D., Wesson, S., Konduri, V., Hofferek, C. J., Vazquez-Perez, J., Blaire, E., . . . Hal- pert, M. M. (2020, September). A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canineosteoarthritispain. Pain, 161(9), 2191– 2202. doi:doi.org/10.1097/j.pain.0000000000001896 Wakshlag, J. J., Schwark, W. S., Deabold, K. A., Talsma, B. N., Cital, S., Lyubimov, A., . . . Zakharov, A. (2020). Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetra- hydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract. Frontiers in Veterinary Science, 7(505). doi:doi: 10.3389/fvets.2020.00505 de una terapia multimodal incluyendo gabapentina y ami- triptilina (Brioschi, et al., 2020). En otro estudio, la Dra. Kogan demostró que 22 de los 32 perros con dolor crónico debido a osteoartritis que recibieron un extracto completo de cáñamo pudieron reducir o descontinuar el tratamiento con gabapen- tina sin afectar el nivel de dolor, movilidad o calidad de vida (Kogan, Hellyer, & Downing, 2020). El Dr. Verrico encontró que altas dosis de CBD (20 mg/Kg de CBD aislado liposomal o 50 mg/kg de CBD aislado no-liposomal) durante cuatro semanas fueron efectivas en manejar el dolor crónico sin consecuencias a nivel de patología clínica (Verrico, et al., 2020). De seguro que en el transcurso de este año se publicarán otros ensayos, algunos de ellos patrocinados por ElleVet™/ ElleVance®, pero una cosa es segura: no hay nada que temer al momento de usar fitocannabinoides de calidad para asistir a nuestros pacientes. (Chicoine, et al., 2020) (Vaughn, Kulpa, & Paulionis, 2020) (GW Pharmaceuticals, 2018). Autor: Germán Graff Veterinario y MBA https://www.linkedin.com/in/germangraff/